Acadia Pharmaceuticals Inc Revenue Growth Rates (ACAD), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Acadia Pharmaceuticals Inc   (NASDAQ: ACAD)
 

ACAD's Revenue Growth by Quarter and Year

Acadia Pharmaceuticals Inc 's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/ACAD/growth
https://api.csimarket.com/api/v1/companies/ACAD/fundamentals
https://api.csimarket.com/api/v1/companies/ACAD/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
ACAD Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 342.29
2nd Quarter June 307.96
1st Quarter March 268.06
FY 918.31

ACADs Annual Revenue
Acadia Pharmaceuticals Inc 's Revenue in the fiscal year 2025 $ 1,071.51 millions
Acadia Pharmaceuticals Inc 's Revenue in the fiscal year 2024 $ 957.80 millions
Acadia Pharmaceuticals Inc 's Revenue in the fiscal year 2023 $ 726.44 millions
Acadia Pharmaceuticals Inc 's Revenue in the fiscal year 2022 $ 517.24 millions
Acadia Pharmaceuticals Inc 's Revenue in the fiscal year 2021 $ 484.15 millions




ACAD Revenue third quarter 2026 Y/Y Growth Comment
Acadia Pharmaceuticals Inc reported Revenue improvement of 22.85% year on year in the third quarter 2026, to $ 342.29 millions, this is lower than Acadia Pharmaceuticals Inc 's recent average Revenue surge of 8635.68%.

Looking into third quarter 2026 results within Major Pharmaceutical Preparations industry 91 other companies have achieved higher Revenue growth. While Acadia Pharmaceuticals Inc ' s Revenue rise of 22.85% ranks overall at the positon no. 1234 in the third quarter 2026.


ACAD Revenue ( Y/Y Growth %) 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 22.85 %
2nd Quarter June 16.4 %
1st Quarter March 9.72 %
FY   -

Financial Statements
Acadia Pharmaceuticals Inc 's third quarter 2026 Revenue $ 342.29 millions ACAD's Income Statement
Acadia Pharmaceuticals Inc 's third quarter 2025 Revenue $ 278.63 millions Quarterly ACAD's Income Statement


ACAD Revenue (Quarter on Quarter Growth %)

 2026
 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September 11.15 %
2nd Quarter June 14.88 %
1st Quarter March -5.61 %
FY (Year on Year)   -


Back to ACAD Growth rate Comparisons >> Back to ACAD Growth rate Comparisons >>


Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #92
Healthcare Sector #225
Overall #1234

Revenue Y/Y Growth Statistics
High Average Low
382050 % 8635.68 % -99.96 %
(Mar 31 2017)   (Dec 31 2015)
Revenue third quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #92
Healthcare Sector #225
Overall #1234
Revenue Y/Y Growth Statistics
High Average Low
382050 % 8635.68 % -99.96 %
(Mar 31 2017)   (Dec 31 2015)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Acadia Pharmaceuticals Inc 's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
313233.33 % 5491.44 % -99.99 %
(Dec 31 2014)  


ACAD's III. Quarter Q/Q Revenue Comment
Acadia Pharmaceuticals Inc achieved in the III. Quarter 2026 below company average Revenue rise of 11.15% quarter on quarter, to $ 342.29 millions.

Although the III. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the III. Quarter surge, eclipses the 5.31% growth in the III. Quarter a year ago

Within Major Pharmaceutical Preparations industry 51 other companies have achieved higher Revenue quarter on quarter growth. While Acadia Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 640.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #52
Healthcare Sector #113
Overall #640
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #52
Healthcare Sector #113
Overall #640
Revenue Q/Q Growth Statistics
High Average Low
313233.33 % 5491.44 % -99.99 %
(Dec 31 2014)  


ACAD's III. Quarter Q/Q Revenue Comment
Acadia Pharmaceuticals Inc achieved in the III. Quarter 2026 below company average Revenue rise of 11.15% quarter on quarter, to $ 342.29 millions.

III. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 5.31% in the III. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 51 other companies have achieved higher Revenue quarter on quarter growth. While Acadia Pharmaceuticals Inc 's Revenue growth quarter on quarter, overall rank is 640.


Acadia Pharmaceuticals Inc 's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2026)		 12 Months Ending (Jun 30 2026) 12 Months Ending (Mar 31 2026) 12 Months Ending (Dec 31 2025) 12 Months Ending (Sep 30 2025)
Cumulative Revenue 12 Months Ending $ 1,202.30
Y / Y Revenue Growth (TTM) 14.82 %
Year on Year Revenue Growth Overall Ranking # 1143
Seqeuential Revenue Change (TTM) 5.59 %
Seq. Revenue Growth (TTM) Overall Ranking # 2389


Cumulative Revenue growth Comment
Although Acadia Pharmaceuticals Inc 's Annual Revenue growth year on year were below company's average 2280.39% , Revenue announced in the Sep 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 14.82% year on year, from 11.75% in Jun 30 2026.

In the Healthcare sector 210 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 269 to 1143.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 110
Healthcare Sector # 211
Overall # 1143

Revenue TTM Y/Y Growth Statistics
High Average Low
53363.93 %
 2280.39 %
-99.87 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 110
Sector # 342
S&P 500 # 2389
Cumulative Revenue growth Comment
Although Acadia Pharmaceuticals Inc 's Annual Revenue growth year on year were below company's average 2280.39% , Revenue announced in the Sep 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 14.82% year on year, from 11.75% in Jun 30 2026.

In the Healthcare sector 210 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 269 to 1143.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 110
Healthcare Sector # 211
Overall # 1143

Revenue TTM Y/Y Growth Statistics
High Average Low
53363.93 %
2280.39 %
-99.87 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 110
Sector # 342
S&P 500 # 2389




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ACAD's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue rise for the quarter ending Sep 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2026
Mirum Pharmaceuticals Inc 39.63%$ 39.629 millions
Caredx Inc 39.29%$ 39.285 millions
Halozyme Therapeutics Inc 39.15%$ 39.154 millions
Eli Lilly And Company38.61%$ 38.613 millions
Myomo Inc 37.42%$ 37.416 millions
Editas Medicine Inc 37.41%$ 37.412 millions
Beyond Air Inc 36.55%$ 36.545 millions
Clearpoint Neuro Inc 36.27%$ 36.271 millions
Regeneron Pharmaceuticals Inc 36.27%$ 36.265 millions
Travere Therapeutics Inc 36.22%$ 36.215 millions
Omada Health Inc 36.13%$ 36.133 millions
Guardant Health Inc 36.12%$ 36.116 millions
Natera Inc 34.08%$ 34.077 millions
Establishment Labs Holdings Inc 34.08%$ 34.075 millions
Beone Medicines Ltd 33.86%$ 33.861 millions
Ceribell Inc 33.72%$ 33.721 millions
Zomedica Corp 33.12%$ 33.123 millions
Intuitive Surgical Inc 32.71%$ 32.714 millions
Adc Therapeutics Sa32.20%$ 32.197 millions
Biomarin Pharmaceutical Inc32.02%$ 32.019 millions
The Pennant Group Inc 31.96%$ 31.965 millions
Beta Bionics Inc 30.92%$ 30.923 millions
Cadre Holdings inc 30.36%$ 30.362 millions
Krystal Biotech Inc 30.21%$ 30.206 millions
Sight Sciences Inc 29.83%$ 29.828 millions
Ge Healthcare Technologies Inc 29.41%$ 29.413 millions
Moderna Inc 29.23%$ 29.232 millions
Sonoma Pharmaceuticals Inc 28.02%$ 28.016 millions
Ani Pharmaceuticals Inc27.64%$ 27.638 millions
Geron Corporation27.45%$ 27.448 millions


About Acadia Pharmaceuticals Inc Revenue Growth Rates (ACAD), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

What’s included here

Company: Acadia Pharmaceuticals Inc (CIK 1070494).

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Accession: 0001193125-26-447794
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: Acadia Pharmaceuticals Inc’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.